Stratasys Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 results showed stable recurring revenue and strong growth in defense and dental segments, despite a 2.4% year-over-year revenue decline and margin pressures from tariffs and FX. Guidance for 2026 was reiterated, with sequential growth and increased consumables revenue expected.
Fiscal Year 2025
-
2025 saw resilient performance with positive adjusted income and cash flow despite revenue and margin pressures, driven by cost controls and growth in high-value manufacturing sectors. 2026 guidance anticipates sequential revenue growth, improved margins, and continued investment, with FX and tariffs as key headwinds.
-
Q3 2025 saw stable product revenue, improved operating cash flow, and positive adjusted EPS despite macro headwinds and tariff pressures. Strategic wins in aerospace, defense, and dental, plus cost discipline, support reaffirmed 2025 guidance and margin improvement into 2026.
-
Q2 2025 saw slight revenue growth and improved profitability, driven by cost controls and strong recurring revenue, despite macro uncertainty and delayed large deals. Strategic partnerships and new product launches are expanding use cases in key sectors, with a strong cash position supporting future growth.
-
First-quarter results showed resilient recurring revenue and improved profitability despite lower year-over-year revenue, supported by cost controls and a $120M investment. Guidance for 2025 was reiterated and raised for earnings, with strong cash and no debt.
Fiscal Year 2024
-
Revenue and profitability declined in 2024 due to macro headwinds, but gross margins improved and cash flow turned positive. 2025 guidance anticipates sequential revenue growth, higher profitability, and continued investment in innovation, with a strong balance sheet and new capital from Fortissimo Capital.
-
Q3 saw a return to adjusted profitability, improved margins, and strong recurring consumables growth despite lower hardware sales. Cost-saving initiatives and new product launches position the company for higher margins and profitability in 2024, with a $50M share repurchase underway.
-
Q2 2024 saw a 13.6% revenue decline but improved margins and strong consumables growth, reflecting robust system utilization. Major restructuring aims for $40M in annual savings and an 8% EBITDA margin in 2025, with continued investment in innovation and a focus on high-value manufacturing, dental, and medical applications.